Cymex Cream

Երկիր: Իռլանդիա

Լեզու: անգլերեն

Աղբյուրը: HPRA (Health Products Regulatory Authority)

Ակտիվ բաղադրիչ:

Cetrimide; Chlorocresol; Dimeticone; Urea

Հասանելի է:

Actavis Group PTC ehf

ATC կոդը:

D08AJ; D08AJ04

INN (Միջազգային անվանումը):

Cetrimide; Chlorocresol; Dimeticone; Urea

Դոզան:

Per Cent

Դեղագործական ձեւ:

Cream

Ռեկվիզորի տեսակը:

Product not subject to medical prescription

Թերապեւտիկ տարածք:

Quaternary ammonium compounds; cetrimide

Լիազորման կարգավիճակը:

Marketed

Հաստատման ամսաթիվը:

1997-04-23

Ապրանքի հատկությունները

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cymex Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For the full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Cream
Smooth white cream with characteristic odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the application to cold sores and cracked lips.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
There are no special hazards associated with the use of cetrimide in
specific patient groups. No special precautions or
modified dosage requirements are, therefore, indicated for its use in
infants, the elderly or during pregnancy or
lactation. No hazardous drug interactions are considered likely.
Adults, elderly and children: apply sparingly every hour for the
relief of cold sores and cracked lips.
Method of administration
Topical application.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substances or to any of the excipients
listed in section 6.1.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Keep out of the reach and sight of children.
For external use only.
If symptoms persist consult your doctor.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known.
Urea
1.0 % w/w
Cetrimide
0.5 % w/w
Dimeticone 350
9.0 % w/w
Chlorocresol
0.1 % w/w
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_9_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_2_
_1_
_6_
_4_
_4_
_8_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 FERTILITY, PREGNANCY AND